Analysis of Immune Markers in Human Cardiac Allograft Recipients and Association With Coronary Artery Vasculopathy

详细信息    查看全文

• 作者：Emilio D. Poggio ; Meagan Roddy ; Jocelyn Riley ; Michael Clemente ; Donald E. Hricik ; Randall Starling ; James B. Young ; Barbara Gus ; Mohamad H. Yamani and Peter S. Heeger
• 刊名：The Journal of Heart and Lung Transplantation
• 出版年：2005
• 出版时间：2005
• 年：2005
• 卷：24
• 期：10
• 页码：1606-1613
• 全文大小：195 K

文摘

Background

Because coronary artery vasculopathy (CAV) is a common cause of late cardiac allograft loss in humans, there is a need to develop and test non-invasive surrogate markers capable of detecting and predicting this disease entity.

Methods

We performed a cross-sectional analysis of immune-based surrogate markers in 65 primary cardiac allograft recipients with or without angiographically documented CAV. Anti-donor cellular immunity was determined by interferon gamma (IFN)-γ enzyme-linked immunosorbent spot (ELISPOT) assays using donor HLA–derived peptides (indirect pathway), and anti-donor alloantibodies were detected by flow cytometry using HLA-coated beads.

Results

Anti-donor cellular and humoral immunity were detected more frequently in patients with CAV (17 of 32, 53.1 % ) than in controls (4 of 33, 12.1 % ) (p < 0.001). Anti-donor cellular and humoral immunity were detected in different sub-groups of CAV patients; peripheral blood lymphocytes (PBLs) from only 1 of 32 CAV patients reacted to donor peptides with simultaneous detection of peripheral anti-donor alloantibodies.

Conclusions

Immune reactivity in cardiac transplant recipients with CAV differs significantly from those without CAV and the detected responses are heterogeneous in nature. Serial assessments of anti-donor immunity using different methods will be required to detect and possibly predict outcome in cardiac transplant recipients.